Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Sites in California: - UCSF at Berkeley Outpatient Center — Berkeley, California
- Alta Bates Summit Medical Center-Herrick Campus Comprehensive Cancer Center — Berkeley, California
- UCSD Medical Center - Encinitas — Encinitas, California
- Palo Alto Medical Foundation - Fremont Center — Fremont, California
- UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion) — La Jolla, California
Phase 3 Recruiting Industry
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Sites in California: - Los Angeles Cancer Network - Anaheim — Anaheim, California
- Kaiser Permanente Anaheim Kraemer Medical Offices — Anaheim, California
- Kaiser Permanente Baldwin Park Medical Center — Baldwin Park, California
- Kaiser Permanente Bellflower Medical Offices — Bellflower, California
- Kaiser Permanente Fontana Medical Center — Fontana, California
Phase 3 Recruiting Industry
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…
Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Sites in California: - Clinical Study Site — Beverly Hills, California
- Clinical Study Site — Beverly Hills, California
- Clinical Study Site — Cerritos, California
- Clinical Study Site — Corona, California
- Clinical Study Site — Duarte, California
Phase 3 Recruiting Industry
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06997497
Sites in California: - Orange Coast Memorial Medical Center ( Site 2007) — Fountain Valley, California
- Los Angeles Hematology Oncology Medical Group ( Site 0084) — Los Angeles, California
- University of California Davis (UC Davis) Comprehensive Cancer Center ( Site 2021) — Sacramento, California
- UCLA Hematology/Oncology - Santa Monica ( Site 0088) — Santa Monica, California
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in California: - USC/Norris Comprehensive Cancer Center — Los Angeles, California
- Local Institution - 0330 — Los Angeles, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center — Orange, California
- Local Institution - 0317 — San Francisco, California
Phase 3 Recruiting Industry
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevaci…
Sponsor: Amgen
NCT ID: NCT06252649
Sites in California: - Providence Saint Jude Medical Center — Fullerton, California
- City of Hope National Medical Center — Long Beach, California
- Cancer and Blood Research Center, LLC — Los Alamitos, California
- California Research Institute — Los Angeles, California
Phase 3 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard…
Sponsor: AbbVie
NCT ID: NCT07525206
Sites in California: - City of Hope National Medical Center /ID# 279449 — Duarte, California
Phase 3 Recruiting Industry
The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer located on the left side of the colon that cannot be safely removed by surgery or has spread to other parts of …
Sponsor: Genmab
NCT ID: NCT07702032
Sites in California: - Valkyrie Clinical Trials - Los Angeles — Los Angeles, California
Phase 3 Recruiting Academic/Other
This phase III trial studies how well pressurized intraperitoneal aerosolized chemotherapy (PIPAC) with mitomycin works versus (vs) standard chemotherapy (leucovorin calcium, fluorouracil, and irinotecan hydrochloride \[FOLFIRI regimen\] p…
Sponsor: City of Hope Medical Center
NCT ID: NCT07271355
Sites in California: - City of Hope Comprehensive Cancer Center — Duarte, California
- City of Hope at Irvine Lennar — Irvine, California
Phase 3 Recruiting Industry
The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer that has recurred after previous treatment and that cannot be safely removed by surgery or has spread to other …
Sponsor: Genmab
NCT ID: NCT07775287
Sites in California: - Valkyrie Clinical Trials - Los Angeles — Los Angeles, California
Phase 2 Recruiting Academic/Other
This phase III trial compares the addition of total ablative therapy to the usual systemic therapy versus the usual systemic therapy alone in treating patients with advanced colorectal cancer that has spread to up to 4 body sites (limited …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in California: - Tower Cancer Research Foundation — Beverly Hills, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- Cedars-Sinai Medical Center — Los Angeles, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in California: - Local Institution - 2129 — Duarte, California
- Local Institution - 2120 — Glendale, California
- Local Institution - 2136 — La Jolla, California
- Local Institution - 2114 — La Jolla, California
- Local Institution - 2121 — Long Beach, California
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in California: - USC Norris Comprehensive Cancer Center — Los Angeles, California
- Sansum Clinic — Santa Barbara, California
- Providence Medical Foundation — Santa Rosa, California
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in California: - UC San Diego Moores Cancer Center — La Jolla, California
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center — Los Angeles, California
- UCLA Hematology/Oncology- Santa Monica — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…
Sponsor: Merus B.V.
NCT ID: NCT03526835
Sites in California: - UCSD — La Jolla, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- Sharp Healthcare — San Diego, California
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in California: - University of California, Los Angeles (UCLA) — Los Angeles, California
- Stanford Cancer Institute, Stanford University — Palo Alto, California
- University of California San Francisco, Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- Sarcoma Oncology Center — Santa Monica, California
Phase 2 Recruiting Industry
This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newl…
Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in California: - Cedars-Sinai Medical Center — Los Angeles, California
- UCLA Medical Center — Santa Monica, California
Phase 2 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…
Sponsor: AbbVie
NCT ID: NCT07023289
Sites in California: - Providence Medical Foundation - Fullerton /ID# 274207 — Fullerton, California
- USC Norris Comprehensive Cancer Center /ID# 274550 — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in California: - UC Irvine/Chao Family Comprehensive Cancer Center — Orange, California
- UCLA — Santa Monica, California
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in California: - Children's Hospital Los Angeles — Los Angeles, California
- Children's Hospital of Orange County — Orange, California
- Lucile Packard Children's Hospital Stanford University — Palo Alto, California
- UCSF Medical Center-Mission Bay — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in California: - Valkyrie Clinical Trials — Los Angeles, California
- Los Angeles Cancer Network — Los Angeles, California
- Pih Health Hematology Medical Oncology — Whittier, California
Phase 2 Recruiting Industry
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Sponsor: AstraZeneca
NCT ID: NCT05489211
Sites in California: - Research Site — Los Angeles, California
- Research Site — San Diego, California
- Research Site — Santa Rosa, California
Phase 1, Phase 2 Recruiting Industry
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07488676
Sites in California: - START Los Angeles — Los Angeles, California
Phase 2 Recruiting Industry
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line …
Sponsor: Oncolytics Biotech
NCT ID: NCT07446322
Sites in California: - Clinical Research Advisors (Beverly Hills) — Beverly Hills, California
- Clinical Research Advisors (Encino) — Encino, California
- Clinical Research Advisors (Korea Town) — Koreatown, California
- Clinical Research Advisors (Downtown LA) — Los Angeles, California
- Clinical Research Advisors (West Hollywood) — Los Angeles, California
Phase 2 Recruiting Industry
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combin…
Sponsor: AbbVie
NCT ID: NCT06820463
Sites in California: - City of Hope National Medical Center /ID# 270255 — Duarte, California
- UCLA - Santa Monica /ID# 270621 — Santa Monica, California